BERLIN, GERMANY — April 4, 2002 — For the first time, there is a therapy that can significantly reduce disease activity for the majority of patients with ankylosing spondylitis (AS), a chronic inflammatory rheumatic disease that often leads to stiffening and subsequent fusion of the spine.
The study, to be published in the April 6 issue of The Lancet, found more than 80 percent of patients treated with Remicade (infliximab) experienced clinical improvement and more than 50 percent had their disease activity reduced by more than half.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!